The corrected release reads:
US FDA ACTION ENABLES MILLIONS OF AMERICAN SMOKERS TO GIVE UP CIGARETTES
Acting under a 2009 statute, the
“For too long, there has been an ideological battle over tobacco
products in the U.S., with cigarette companies at the center of a heated
debate. In our view, and the view of many long-standing tobacco control
advocates, it’s time to put the tobacco wars aside and instead focus on
what’s best for the millions of men and women who smoke in the U.S.,”
In bringing IQOS to market in the U.S., PMI will comply with existing federal and state laws that apply to tobacco products and will likewise follow the additional specific requirements in FDA’s marketing order to minimize any unintended use by never smokers, especially youth.
Shortly after receiving the order, PMI and
CTFK’s letter requested assurances from PMI in relation to the launch of IQOS in the U.S. PMI has adopted a business strategy that aims to replace cigarettes with innovative, smoke-free alternatives. For those who continue smoking, our goal is to maximize adult smoker awareness of and access to alternatives like IQOS, while minimizing use by nonsmokers (and that of youth, in particular). In our reply to CTFK, Dr. Gilchrist emphasized our simple message: “If you don’t smoke, don’t start; if you smoke, quit; if you don’t quit, change. Just as CTFK aims to prevent youth tobacco and nicotine use—which we wholeheartedly support—we also aim for smoke-free adults, a companion goal that we hope CTFK would also support.”
For a complete copy of Dr. Gilchrist’s reply, please click here.
Philip Morris International Media Office
T. +1 (202) 679 7296